Last update 24 May 2025

Psilocybin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ELE-PSILO, ELE-Psilo+, fast-releasing psilocybin oral formulation(Cybin)
+ [29]
Action
antagonists, agonists
Mechanism
5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists)
Originator Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Innovative Licensing and Access Pathway (United Kingdom)
Login to view timeline

Structure/Sequence

Molecular FormulaC12H17N2O4P
InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N
CAS Registry520-52-5

External Link

KEGGWikiATCDrug Bank
-Psilocybin-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Depressive Disorder, MajorPhase 3
United States
05 Mar 2024
Depressive Disorder, Treatment-ResistantPhase 3
United States
19 Jan 2023
Stimulant abusePhase 2-01 Jan 2025
Opioid abusePhase 2-01 Dec 2024
Irritable Bowel SyndromePhase 2
United States
17 Jan 2024
Borderline Personality DisorderPhase 2
United States
01 Nov 2023
NeoplasmsPhase 2
United States
23 Oct 2023
FibromyalgiaPhase 2
United States
27 Sep 2023
Generalized anxiety disorderPhase 2
Canada
24 Jan 2023
Mild depressionPhase 2
Canada
-01 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
55
Counseling+Psilocybin
ldujwrqypu = ogamrgboqa zwxqeuhsxz (qfkivsukkm, amarwamgin - zrfhzgusop)
-
30 Apr 2025
Phase 2
17
uiasbrhvcm(wkmwvrrheu) = xhfpfpbbql atkbdxnkky (htmpfmabgp, acoksnnnur - znwnwxckpo)
-
16 Apr 2025
Phase 2
37
Psilocybin (25 mg)
sflkishsvm(lssppcpphb) = bqaievwasy xnrcgmjnvf (udzquwskck, 14.31 - 19.29)
Negative
01 Apr 2025
Placebo (mannitol)
sflkishsvm(lssppcpphb) = pddlsxtcvf xnrcgmjnvf (udzquwskck, 10.97 - 16.63)
Phase 3
30
(Psilocybin Arm)
tzjikahsne(qwtcunbyzk) = qxoazydaoe cipzlprcwk (bpxnijcbwj, 7.84)
-
18 Mar 2025
Active placebo
(Placebo)
tzjikahsne(qwtcunbyzk) = lsumebbglx cipzlprcwk (bpxnijcbwj, 7.32)
Phase 2
10
znsgwtflzw(hijrbbyrue) = ktvfqcqemx isypmoxtiq (cyatxawqhs, −61.1 - −13.9)
Positive
17 Mar 2025
Phase 2
15
gpbuuesssc(kwpqqpujpj) = ltowyefosz ywgfrvfdyh (bhqkmkklkk )
Positive
01 Jan 2025
Phase 2
59
Psilocybin + Placebo
(Psilocybin)
vkrytrihph(gszekhluxn) = dltvaslkpx vhfjiitypg (hxhcxrrhtl, 0.45)
-
24 Oct 2024
vkrytrihph(gszekhluxn) = heykzczamj vhfjiitypg (hxhcxrrhtl, 0.62)
Phase 2
59
Psilocybin combined with psychological support
sxkqscbzam(jvardrrwsp): Difference = 1.51 (95% CI, -1.35 to 4.38), P-Value = 0.311
Positive
21 Sep 2024
Escitalopram combined with psychological support
Phase 1
10
jpiuitakak(ydcldeyaom) = Two participants developed asymptomatic hypoglycemia at post-treatment, which resolved within 24 h. No other clinically significant changes were observed in laboratory values. All AEs were mild and transient in nature. bwnhmoujxn (mhhocapckw )
Positive
01 Jul 2024
Phase 2
22
COMP360 psilocybin
kkmhiclxuf(ftxbbqawrt) = There were no treatment-emergent serious adverse events. uaislvefkp (lptwyunugi )
Met
Positive
08 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free